Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.
暂无分享,去创建一个
Nobuhiro Yamamoto | Minoru Sakurai | Masaya Orita | Yutaka Nakajima | Koji Ueshima | Masashi Imanishi | Keiko Nakano | Yasuhiro Matsumura | Kouji Hattori | Susumu Toda | Shinji Itou | Daisuke Tanabe | Kenichi Washizuka | Takanobu Araki | Shigeo Matsui | Emiko Imamura | Takao Yamamoto | Hirofumi Ishikawa | Naoko Unami | Kaori Hamada | Fujiko Takamura
[1] C. Cowan,et al. Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres. , 2002, Journal of medicinal chemistry.
[2] M. Sakurai,et al. Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety. , 2008, Journal of medicinal chemistry.
[3] M. Sakurai,et al. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5. , 2009, Journal of medicinal chemistry.
[4] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[5] Nobuhiro Yamamoto,et al. Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV. , 2008, Bioorganic & medicinal chemistry letters.
[6] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[7] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[8] H. Mukaiyama,et al. Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. , 2003, Journal of medicinal chemistry.
[9] A. Mathur,et al. Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity , 1997 .
[10] M. Sakurai,et al. Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. , 2008, Journal of medicinal chemistry.
[11] R. Gregg,et al. Beta 3 agonists. Part 1: evolution from inception to BMS-194449. , 2001, Bioorganic & medicinal chemistry letters.
[12] M. Sawa,et al. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. , 2006, Current medicinal chemistry.
[13] M. Sennitt,et al. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs , 1984, Nature.